DOCSLIB.ORG

Deoxyribozymes As Catalytic Nanotherapeutic Agents Levon M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Deoxyribozymes As Catalytic Nanotherapeutic Agents Levon M Published OnlineFirst February 13, 2019; DOI: 10.1158/0008-5472.CAN-18-2474 Cancer Review Research Deoxyribozymes as Catalytic Nanotherapeutic Agents Levon M. Khachigian Abstract RNA-cleaving deoxyribozymes (DNAzymes) are synthet- and nanosponges, and the emerging role of adaptive ic single-stranded DNA-based catalytic molecules that can immunity underlying DNAzyme inhibition of cancer be engineered to bind to and cleave target mRNA at growth. DNAzymes represent a promising new class of predetermined sites. These have been used as therapeutic nucleic acid–based therapeutics in cancer. This article dis- agents in a range of preclinical cancer models and have cusses mechanistic and therapeutic insights brought about entered clinical trials in Europe, China, and Australia. This by DNAzyme use as nanotools and reagents in a range of review surveys regulatory insights into mechanisms of basic science, experimental therapeutic and clinical appli- disease brought about by use of catalytic DNA in vitro and cations. Current limitations and future perspectives are also in vivo, including recent uses as nanosensors, nanoflowers, discussed. DNAzyme Catalysts: Mechanistic and transfected with commercial delivery agents or electroporated Design Considerations into cells. DNAzyme use in experimental animal models can be hampered by delivery issues, especially in regard to systemic DNAzymes are synthetic single-stranded enzymatic DNA mole- administration (10). This has motivated local delivery meth- cules that bind to their target mRNA via Watson–Crick base odologies in animals, such as intracardiac, intratumoral, and pairing and cleave a specific interbase junction in the mRNA by intraarticular injection, or tissue immersion. Novel biodegrad- a deesterification reaction (1–3). This involves metal-assisted able template-based DNAzymes have recently been developed 0 deprotonation of 2 -hydroxyl in the RNA, producing RNA frag- that facilitate cancer cell recognition and internalization (11). 0 0 0 ments terminating in a 2 ,3 -cyclic phosphate and a 5 -hydroxyl That said, oligonucleotides may not necessarily require a spe- (Fig. 1; ref. 4). DNAzymes were originally developed as catalysts cific delivery vehicle for endosomal or lysosomal seques- in vitro and then used as gene-silencing agents within cells where tration (12), and indeed there are numerous examples of endogenous mRNA is targeted. Breaker and Joyce reported the first DNAzyme efficacy in experimental models without use of any DNAzyme in late 1994, cleaving a ribonucleotide linkage by way carrier. In experimental tumors, this may involve an enhanced 2þ of a transesterification reaction requiring Pb (5). Studies have permeability and retention (EPR) effect (13). DNAzymes have since demonstrated that DNAzymes also use other divalent ions been used in the clinic with or without a specifictransfection 2þ 2þ 2þ as cofactors, including Mg ,Zn , and Ca (6). DNAzyme agent as discussed below. Second, the half-life of the target RNA action is not confined to RNA cleavage; these agents can also would ideally be short and background mRNA expression of 0 catalyze bond formation, such as ligation between the 3 -hydroxyl the target low. Cleavage destabilizes RNA and accelerates its 0 and 5 -triphosphate terminus in RNA (7, 8). The first high- degradation, meaning less protein is produced. In our own resolution (2.8 Å) crystal structure of a DNAzyme in its post- work, we have generated DNAzymes targeting immediate-early catalytic state complexed with RNA was recently reported with genes that are poorly expressed in normal tissues and have one such DNAzyme. Ponce-Salvatierra and colleagues found that relatively short half-lives. For example, c-jun mRNA (targeted the 44 nucleotide RNA-ligating DNAzyme 9DB1 forms a double by the DNAzyme Dz13; ref. 14) rapidly decays with a half-life pseudoknot in complex with a 15-nucleotide RNA strand (9). of 20 minutes (15). The half-life of early growth response-1 This review focuses mainly on RNA-cleaving DNAzymes. (Egr-1) mRNA (targeted by ED5; ref. 16) is even shorter (17). There are several considerations when designing DNAzymes These genes are expressed at low or undetectable levels in as endogenous RNA-cleavage–based inhibitors. First, there uninjured, growth quiescent arteries (14, 16, 18). Third, should be sufficient intracellular accumulation of the oligonu- although target site specificity is prescribed by the choice of cleotide and access to mRNA. Typically in vitro, DNAzymes are bases in the binding arms, DNAzymes, like other antisense- based targeting strategies, can have "off-target" effects, arising from partial complementarity of DNAzyme arm sequences Vascular Biology and Translational Research, School of Medical Sciences, with an unintended target or Toll-like receptors that recognize Faculty of Medicine, University of New South Wales, Sydney, Australia. CpG-motif–containing DNA (TLR-9; ref. 19). This can be Corresponding Author: Levon M. Khachigian, University of New South Wales, addressed experimentally using DNAzymes as controls bearing High Street, Gate 9, Sydney, NSW 2052, Australia. Phone: 61-2-9385-2537; single-nucleotide mutations (e.g., G6>C6) in the 15 nucleotide Fax: 61-2-9385-1797; E-mail: [email protected] 10–23 catalytic domain (i.e., 50-GGC TAG6 CTA CAA CGA-30; doi: 10.1158/0008-5472.CAN-18-2474 refs.1,4),renderingtheDNAzymeunabletocleavebut Ó2019 American Association for Cancer Research. remaining identical to the test DNAzyme in all other www.aacrjournals.org OF1 Downloaded from cancerres.aacrjournals.org on September 25, 2021. © 2019 American Association for Cancer Research. Published OnlineFirst February 13, 2019; DOI: 10.1158/0008-5472.CAN-18-2474 Khachigian R Y O 2’ O O P O 3’ OOH O O - 5’ Figure 1. O HO Mechanism of action by the Y RNA-cleaving 10–23 DNAzyme. The 10–23 DNAzyme (depicted here with R O þ OOH O 9 9 nucleotide arms) hybridizes O N P OOH N with its target RNA through O N N O N – O Watson Crick base pairing and N – N N N N N catalyzes cleavage between an N N 3’ N R N N unpaired purine (R) and a paired N N N N N N N pyrimidine (Y) through an internal N N G N 5’ N N A phosphoester transfer reaction N G 0 N G whereby the 2 -hydroxyl attacks the 5’ N N C N adjacent phosphodiester bond. This 3’ N C T results in one fragment ending with a 10-23 20,30-cyclic phosphate and the other A DNAzyme A ending with a 50-hydroxyl. Other A G sugar phosphates in the DNAzyme or C C RNA are not shown for simplicity. A T R, A or G (purine); Y,CorU (pyrimidine); N, G or A or T or C. © 2018 American Association for Cancer Research respects (20). Another way is to test for TLR9/NF-kBactivation rat carotid arteries, a finding later confirmed by Liu and col- alongside reference oligonucleotides (21). Such "off-target" leagues who used ED5 to inhibit Egr-1 and TGFb expression, effects should not be confused with DNAzymes targeting resulting in increased levels of nitric oxide synthase and NO master regulators, such as transcription factors, where and preservation of endothelial cell function (31). Wang and that DNAzyme would also be expected to affect other genes colleagues further found ED5 reduced levels of Egr-1 and reliant on the targeted factor. Fourth, DNAzyme stability platelet-derived growth factor (PDGF)-BB, cdk4, cyclin D1, against nucleolytic attack is typically achieved by structural monocyte chemotactic factor (MCP)-1, and intercellular adhe- modifications such as inverted bases, phosphorothioate or sion molecule (ICAM)-1 (32). In a rat autologous vein graft phosphoramidate linkages, locked nucleic acids, and 20-meth- model, Liu and colleagues used essentially the same DNAzyme oxy substitutions. These modifications can be incorporated (EDRz) to suppress Egr-1 expression, SMC proliferation, and during oligonucleotide manufacture. Fifth, although there are intimal thickening (33). EDRz also reduced formation of potentially hundreds of target sites in a typical mRNA, con- abdominal aortic aneurysm in rats, suppressing Egr-1, matrix ventional sequence selection for a DNAzyme is time-consum- metalloproteinase (MMP)-2, and MMP-9 levels (34). Egr-1 ing, labor-intensive, and cumbersome (22). Investigators have DNAzymes also inhibited intimal thickening in a rat model used predictions on RNA folding, low free energy, and second- of carotid ligation following adventitial delivery (35), reduced ary structure (23, 24), but this does not ensure DNAzyme myocardial infarct size in the area at risk in a rat model of efficacy (14). Finally, it should be noted that DNAzyme cata- myocardial ischemia–reperfusion injury (36), in-stent resteno- lytic efficacy also depends on the length of binding arms even sis in a porcine model of stenting (37), and improved for a single target site (6, 21, 25). left ventricular systolic function in porcine models of myocar- dial ischemia–reperfusion injury and intracoronary deliv- DNAzymes as Versatile Experimental ery (38, 39). Dickinson and colleagues further demonstrated the effects of Egr-1 suppression on pulmonary vascular remo- Drugs in Noncancerous Settings deling in an experimental flow-associated pulmonary arterial Since the discovery of the 10–23 DNAzyme by Santoro and hypertension rat model. Intravenous administration of ED5 (in Joyce reported in 1997, so named from the 23rd clone from the DOTAP) reduced pulmonary vascular Egr-1 expression, vascu- 10th round of an in vitro selection procedure (1, 4), DNAzymes lar remodeling and neointima formation, and reduced expres- have been used as experimental drugs in a diverse range of models. sion of PDGF-B, TGFb, IL6, and p53 (40). ED5 also inhibited New monovalent cation-dependent RNA-cleaving DNAzymes, pulmonary vascular resistance, right ventricular (RV) systolic such as Ag10c (26, 27), Ce13d (28), EtNa (29), and NaA43 (30), pressure, and RV hypertrophy. Nakamura and colleagues deliv- with catalytic domains that differ from 10–23 have also emerged, ered ED5 into interstitial fibroblasts in vivo by electroporation and it will be interesting to see how these progress within via the ureter that reduced interstitial fibrosis in obstructed preclinical systems.
Load more

Recommended publications
  • IAIS Abstracts Melbourne 2005
    Book of Abstracts List of Committees Organising Committee Steering Committee Chairs Ian Adcock, UK John Hamilton, Australia Ian Ahnfelt-Ronne, Denmark Eric Morand, Australia Gareth Bowen, UK Michel Chignard, France Gary Anderson, Australia John Hamilton, Australia Gareth Bowen, UK Gordon Letts, USA Andrew Cook, Australia Lisa Marshall, USA Michael Hickey, Australia Tineke Meijers, Canada Gordon Letts, USA Tatsutoshi Nakahata, Japan Alan Lewis, USA Wim van den Berg, The Netherlands Lisa Marshall, USA Kouji Matsushima, Japan Amy Roshak, USA Glen Scholz, Australia Ross Vlahos, Australia Young Investigator Award Committee Program Committee Chair: Chair: Glen Scholz, Australia Michael Hickey, Australia Laurent Audoly, Canada Andrew Cook, Australia Susan Brain, UK John Hamilton, Australia John Schrader, Canada Lisa Marshall, USA Vincent Lagente, France Eric Morand, Australia Kouji Matsushima, Japan Glen Scholz, Australia Ross Vlahos, Australia For enquiries after the Congress please contact the Congress Secretariat: ICMS Pty Ltd Attention: 7th World Congress on Infl ammation 2005 84 Queensbridge Street Southbank Vic 3006 Australia P: +61 3 9682 0244 F: +61 3 9682 0288 E: infl [email protected] W: www.infl ammation2005.com Contents Sunday 21 August 2005 Abstract No. Page Title Morning 1001 — Plenary 1: Peter Doherty 1002 -1004 — Symposium 1: Chronic Obstructive Pulmonary Disease 1005 - 1008 S 85 Symposium 2: Arthritis Afternoon 1010 - 1013 S 85 Focus Group 1: Understanding Infl ammation through Genetics, Genomics and Proteomics 1014 - 1018 S 86 Focus Group 2: Asthma 1019 - 1022 S 88 Focus Group 3: The Immunoregulatory Response 1023 -1027 S 89 Focus Group 4; Structure-Based Drug Design 1028 - 1032 S 90 Focus Group 5: Chronic Obstructive Pulmonary Disease 1033 - 1037 S 90 Focus Group 6: Rheumatic Diseases Monday 22 August 2005 Abstract No.
    [Show full text]
  • Deoxyribozymes As Catalytic Nanotherapeutic Agents Levon M
    Published OnlineFirst February 13, 2019; DOI: 10.1158/0008-5472.CAN-18-2474 Cancer Review Research Deoxyribozymes as Catalytic Nanotherapeutic Agents Levon M. Khachigian Abstract RNA-cleaving deoxyribozymes (DNAzymes) are synthet- and nanosponges, and the emerging role of adaptive ic single-stranded DNA-based catalytic molecules that can immunity underlying DNAzyme inhibition of cancer be engineered to bind to and cleave target mRNA at growth. DNAzymes represent a promising new class of predetermined sites. These have been used as therapeutic nucleic acid–based therapeutics in cancer. This article dis- agents in a range of preclinical cancer models and have cusses mechanistic and therapeutic insights brought about entered clinical trials in Europe, China, and Australia. This by DNAzyme use as nanotools and reagents in a range of review surveys regulatory insights into mechanisms of basic science, experimental therapeutic and clinical appli- disease brought about by use of catalytic DNA in vitro and cations. Current limitations and future perspectives are also in vivo, including recent uses as nanosensors, nanoflowers, discussed. DNAzyme Catalysts: Mechanistic and transfected with commercial delivery agents or electroporated Design Considerations into cells. DNAzyme use in experimental animal models can be hampered by delivery issues, especially in regard to systemic DNAzymes are synthetic single-stranded enzymatic DNA mole- administration (10). This has motivated local delivery meth- cules that bind to their target mRNA via Watson–Crick base odologies in animals, such as intracardiac, intratumoral, and pairing and cleave a specific interbase junction in the mRNA by intraarticular injection, or tissue immersion. Novel biodegrad- a deesterification reaction (1–3). This involves metal-assisted able template-based DNAzymes have recently been developed 0 deprotonation of 2 -hydroxyl in the RNA, producing RNA frag- that facilitate cancer cell recognition and internalization (11).
    [Show full text]
  • Effect of EBV LMP1 Targeted Dnazymes on Cell Proliferation And
    Cancer Gene Therapy (2005) 12, 647–654 r 2005 Nature Publishing Group All rights reserved 0929-1903/05 $30.00 www.nature.com/cgt Effect of EBV LMP1 targeted DNAzymes on cell proliferation and apoptosis Zhong-Xin Lu,1 Mao Ye,1 Guang-Rong Yan,1 Qun Li,1 Min Tang,1 Leo M Lee,2 Lun-Quan Sun,3 and Ya Cao1 1Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China; 2Laboratory of Molecular Technology SAIC-Frederick, National Cancer Institute, Frederick, Maryland, USA; and 3St Vincent’s Clinical School, Faculty of Medicine, The University of New South Wales, Sydney, Australia. The latent membrane protein (LMP1) encoded by Epstein–Barr virus (EBV) has been suggested to be one of the major oncogenic factors in EBV-mediated carcinogenesis. RNA-cleaving DNA enzymes are catalytic nucleic acids that bind and cleave a target RNA in a highly sequence-specific manner. In this study, we explore the potential of using DNAzymes as a therapeutic approach to EBV- associated carcinomas by targeting the LMP1 gene. In all, 13 different phosphorothioate-modified ‘‘10–23’’ deoxyribozymes (DNAzymes) were designed and synthesized against the LMP1 mRNA and transfected into B95-8 cells, which constitutively express the LMP1. Fluorescence microscopy was used to examine the cellular uptake and distribution in B95-8 cells. As demonstrated in Western blots, three out of 13 deoxyribozymes significantly downregulated the expression of LMP1 in B95-8 cells. These DNAzymes were shown to markedly inhibit B95-8 cell growth compared with a disabled DNAzyme and untreated controls, as determined by an alamarBlue Assay.
    [Show full text]
  • Targeting the Transcription Factor C-Jun in Cervical Cancer Cells
    Targeting the Transcription Factor c-Jun in Cervical Cancer Cells Grace Pei Chien Yee Centre for Vascular Research, School of Medical Sciences, University of New South Wales, Australia A thesis submitted to the University of New South Wales for the degree of Doctor of Philosophy (PhD) September 2013 ORIGINALITY STATEMENT ‘I hereby declare that this submission is my own work and to the best of my knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the award of any other degree or diploma at UNSW or any other educational institution, except where due acknowledgement is made in the thesis. Any contribution made to the research by others, with whom I have worked at UNSW or elsewhere, is explicitly acknowledged in the thesis. I also declare that the intellectual content of this thesis is the product of my own work, except to the extent that assistance from others in the project's design and conception or in style, presentation and linguistic expression is acknowledged.’ Signed …………………………………………….............. Date …………………………………………….............. i ABSTRACT Despite the development of vaccines for human papillomaviruses (HPV) in cervical cancer and other efforts to improve therapy, deaths still average 275,000 annually worldwide, with most women succumbing to recurrent or metastatic disease. The c-Jun oncogene is a subunit of the activating protein-1 (AP-1) transcription factor and is strongly expressed in cervical cancer, regulating the expression of HPV16 and 18 genes. AP-1 plays a major role in cell growth, migration and apoptosis in many cell types.
    [Show full text]
  • Ep 1485109 B1
    (19) TZZ__Z_T (11) EP 1 485 109 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/113 (2010.01) A61K 31/7088 (2006.01) 02.10.2013 Bulletin 2013/40 A61P 9/00 (2006.01) A61P 9/10 (2006.01) A61P 35/00 (2006.01) C12Q 1/68 (2006.01) (21) Application number: 03702205.0 (86) International application number: (22) Date of filing: 27.02.2003 PCT/AU2003/000237 (87) International publication number: WO 2003/072114 (04.09.2003 Gazette 2003/36) (54) VASCULAR THERAPEUTICS GEFÄSSTHERAPEUTIKA TRAITEMENT VASCULAIRE (84) Designated Contracting States: • BISWAL S. ET AL.: "Inhibition of cell proliferation AT BE BG CH CY CZ DE DK EE ES FI FR GB GR and AP-1 activity by Acrolein in human A549 lung HU IE IT LI LU MC NL PT SE SI SK TR adenocarcinoma cells due to thiol imbalance and covalent modifications" CHEMICAL RESEARCH (30) Priority: 27.02.2002 AU PS078002 IN TOXICOLOGY, vol. 15, no. 2, February 2002 (2002-02), pages 180-186, XP002531768 (43) Date of publication of application: • SUGGS W.D. ET AL.: "Antisense 15.12.2004 Bulletin 2004/51 oligonucleotides to c- fos and c- jun inhibit intimal thickening in a rat vein graft model" SURGERY, (73) Proprietor: NewSouth Innovations Pty Limited vol. 126, 1999, pages 443-449, XP002531769 Sydney NSW 2052 (AU) • YOSHIDA S. ET AL.: "Involvement of Interleukin- 8, Vascular Endothelial Growth Factor, and Basic (72) Inventor: KHACHIGIAN, Levon, Michael Fibroblast Growth Factor in Tumor Necrosis Ryde, New South Wales 2112 (AU) Factor alpha-dependent angiogenesis" MOLECULAR AND CELLULAR BIOLOGY, vol.
    [Show full text]
  • Review Article the Molecular Pathogenesis of Osteosarcoma: a Review
    Hindawi Publishing Corporation Sarcoma Volume 2011, Article ID 959248, 12 pages doi:10.1155/2011/959248 Review Article The Molecular Pathogenesis of Osteosarcoma: A Review Matthew L. Broadhead,1 Jonathan C. M. Clark,1 Damian E. Myers,1 Crispin R. Dass,2 and Peter F. M. Choong1, 3 1 Department of Orthopaedics, Department of Surgery, University of Melbourne, St. Vincent’s Hospital, SVHM, L3, Daly Wing, 35 Victoria Parade, Fitzroy VIC 3065, Australia 2 School of Biomedical and Health Sciences, Victoria University, St. Albans, VIC 3021, Australia 3 Sarcoma Service, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia Correspondence should be addressed to Peter F. M. Choong, [email protected] Received 15 September 2010; Accepted 21 February 2011 Academic Editor: H. Kovar Copyright © 2011 Matthew L. Broadhead et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapid growth and primarily affects adolescents and young adults. The 5-year survival rate for osteosarcoma is 60%–70%, with no significant improvements in prognosis since the advent of multiagent chemotherapy. Diagnosis, staging, and surgical management of osteosarcoma remain focused on our anatomical understanding of the disease. As our knowledge of the molecular pathogenesis of osteosarcoma expands, potential therapeutic targets are being identified. A comprehensive understanding of these mechanisms is essential if we are to improve the prognosis of patients with osteosarcoma through tumour-targeted therapies.
    [Show full text]
  • Role of Transcription Factor C-Jun in Acute Inflammation and Intimal Thickening in Bypassed Vein Grafts: Insights Using Dnazymes
    Role of transcription factor c-Jun in acute inflammation and intimal thickening in bypassed vein grafts: insights using DNAzymes Alla Waldman, MD Centre for Vascular Research Department of Pathology, The University of New South Wales Submitted for the degree of Doctor of Philosophy (PhD) Thesis Outline 2 TABLE OF CONTENTS ACKNOWLEDGMENT 3 ABSTRACT 4 PUBLICATIONS, PRESENTATIONS, AWARDS 12 ABBREVIATIONS 13 THESIS OUTLINE Chapters 1-3: INTRODUCTION 16 Chapters 4-6: RESULTS AND METHODS 90 Chapter 7: CONCLUSIONS AND FUTURE DIRECTIONS 163 REFERENCES 170 Thesis Outline 3 Acknowledgement I would like to thank my supervisor Professor Levon Khachigian for his patience, guidance, encouragement and continuous support during my PhD. I was very privileged to be part of his research group and to work with many very talented and successful scientists. I am very grateful to Professor Michael Perry, my co-supervisor for his teaching and support. His help in setting up microcirculation studies was invaluable and is greatly appreciated! I would like to thank my colleagues in Levon's lab, in particular Roger Fahmy for his extraordinary teaching, help and support; Dr Ravinay Bhindi for his valuable advice on my animal projects and willingness to help and Dr Valerie Midgley for her help in teaching, her friendship and good humour we shared so many times during the last 3 years. I would like to thank my amazing family, my parents Alex and Raissa Valdman and my brother Michael for always being there for me, for giving me the best opportunities in life to become who I am today. To my husband Joseph and my son Boris, I would have never made it without their unconditional support of my career, your love and friendship.
    [Show full text]
  • Medicinal Chemistry
    Special Report Special Focus Issue: Frontiers in Nucleic Acid-Based Drug R&D Future For reprint orders, please contact [email protected] Medicinal 7 Chemistry Special Report 2015/08/28 DNAzyme-based therapeutics for cancer treatment Future Med. Chem. Gene-silencing strategies based on catalytic nucleic acids have been rapidly developed Shujun Fu1 & Lun-Quan Sun*,1 in the past decades. Ribozymes, antisense oligonucleotides and RNA interference 1Center for Molecular Medicine, Xiangya have been actively pursued for years due to their potential application in gene Hospital, Central South University Changsha, China 410008 inactivation. Pioneered by Joyce et al., a new class of catalytic nucleic acid composed *Author for correspondence: of deoxyribonucleotides has emerged via an in vitro selection system. The therapeutic [email protected] potential of these RNA-cleaving DNAzymes have been shown both in vitro and in vivo. Although they rival the activity and stability of synthetic ribozymes, they are limited by inefficient delivery to the intracellular targets. Recent successes in clinical testing of the DNAzymes in cancer patients have revitalized the potential clinical utility of DNAzymes. 00 Due to the simple four-nucleotide chemistry system was based on hydrolytic cleavage of and standard Watson–Crick pairing, nucleic a phosphodiester and nested PCR [1–3] . First, acids are appealing targets for exogenous they established a pool of 1014 ssDNA mol- regulation of gene expression. Utilizing ecules. Each one contained a 5′ biotin moi- hybridization to achieve artificial gene sup- ety, followed by a 50 random deoxyribonu- pression is mostly related to the involvement cleotides domain which was flanked by fixed of single-stranded oligodeoxynucleotides and sequence.
    [Show full text]
  • Small-Molecule Nucleic-Acid-Based Gene-Silencing Strategies
    Chapter 8 Small-molecule Nucleic-acid-based Gene-silencing Strategies Zhijie Xu and Lifang Yang Additional information is available at the end of the chapter http://dx.doi.org/10.5772/62137 Abstract Gene-targeting strategies based on nucleic acid have opened a new era with the develop‐ ment of potent and effective gene intervention strategies, such as DNAzymes, ribozymes, small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), aptamers, decoys, etc. These technologies have been examined in the setting of clinical trials, and several have recently made the successful transition from basic research to clinical trials. This chapter discusses progress made in these technologies, mainly focusing on Dzs and siR‐ NAs, because these are poised to play an integral role in antigene therapies in the future. Keywords: Gene-targeting strategies, DNAzymes, siRNAs, basic research, clinical trials 1. Introduction Over the past decade, it is known that the advent of oligonucleotide-based gene inactivation agents have provided potential for these to serve as analytical tools and potential treatments in a range of diseases, including cancer, infections, inflammation, etc. During this time, many genes have been targeted by specifically engineered agents from different classes of small- molecule nucleic-acid-based drugs in experimental models of disease to probe, dissect, and characterize further the complex processes that underpin molecular signaling. Subsequently, a number of molecules have been examined in the setting of clinical trials, and several have recently made the successful transition from the bench to the clinic, heralding an exciting era of gene-specific treatments. This is particularly important because clear inadequacies in present therapies account for significant morbidity, mortality, and cost.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,686,128 B2 Khachigian (45) Date of Patent: Apr
    USOO8686 128B2 (12) United States Patent (10) Patent No.: US 8,686,128 B2 Khachigian (45) Date of Patent: Apr. 1, 2014 (54) AGENT FORTARGETING C-JUN MRNA Adamis, A.P. et al. (1999). "Angiogenesis and Ophthalmic Disease.” Angiogenesis 3(1):9-14. Ahmad, M. etal. (Feb. 20, 1998). “Role of Activating Protein-1 in the (76) Inventor: Levon Michael Khachigian, Ryde (AU) Regulation of the Vascular Cell Adhesion Molecule-1 Gene Expres sion by Tumor Necrosis Factor-O.” The Journal of Biological Chem (*) Notice: Subject to any disclaimer, the term of this istry 278(8):4616-4621. patent is extended or adjusted under 35 Alfranca, A. etal. (Jan. 2002). “c-Jun and Hypoxia-Inducible Factor U.S.C. 154(b) by 0 days. 1 Funcitonally Cooperate in Hypoxia-Induced Gene Transcription.” Molecular and Cellular Biology 22(1):12-22. (21) Appl. No.: 13/548,142 Bhindi, R. et al. (Oct. 2007). “DNA Enzymes, Short Interfering RNA, and the Emerging Wave of Small-Molecule Nucleic Acid-Based Gene-Silencing Strategies.” The American Journal of Pathology (22) Filed: Jul. 12, 2012 17(4): 1079-1088. Biswals, S. et al. (Feb. 2002). “Inhibition of Cell Proliferation and (65) Prior Publication Data AP-1 Activity by Acrolein in Human A549 Lung Adenocarcinoma US 2013/0237696A1 Sep. 12, 2013 Cells Due to Thiol Imbalance and Covalent Modifications.” Chemi cal Research in Toxicology 15(2): 180-186. Blei. F. et al. (Jun. 1993). “Mechanism of Action of Angiostatic Steroids: Suppression of Plasminogen Activator Activity via Stimu Related U.S. Application Data lation of Plasminogen Activator Inhibitor Synthesis,” J.
    [Show full text]